

CONTENTS

1. PATHOPHYSIOLOGY OF PAIN IN INFLAMMATION	5
VERONICA BILD	
1.1. INTRODUCTION	5
1.2. INFLAMMATORY PROCESS	7
1.3. PROCESS OF PAIN IN ITIATION AND TRANSMISSION	8
1.3.1. <i>Notion of nociception</i>	9
1.4. TYPES OF RECEPTORS INVOLVED IN NOCICEPTION	12
1.4.1. <i>Vanilloid receptors</i>	12
1.4.2. <i>Proton receptors</i>	15
1.4.3. <i>Purinergic receptors</i>	17
1.4.4. <i>Ionic channels</i>	19
1.4.5. <i>Opioid receptors</i>	23
1.4.6. <i>Cannabinoid receptors</i>	26
1.5. MEDIATORS INVOLVED IN INFLAMMATORY PAIN	29
- PERIPHERAL SENSIBILIZATION	
1.5.1. <i>Bradikinin</i>	29
1.5.2. <i>Serotonin</i>	35
1.5.3. <i>Chemical factors produced during tissue injury</i>	36
1.5.4. <i>Cytokines</i>	39
1.5.5. <i>Arachidonic acid metabolism products</i>	39
1.5.6. <i>Neurogenic substances</i>	43
1.5.7. <i>Growth factors</i>	45
1.6. NEURONAL PLASTICITY - CENTRAL SENSIBILIZATION	46
1.6.1. <i>Transcriptional and post-translational plasticity</i>	47
1.6.2. <i>State-dependent sensorial processing</i>	47
2. PHARMACOTHERAPEUTIC POSSIBILITIES IN	
INFLAMMATORY PAIN	
VERONICA BILD	
2.1. INTRODUCTION	53
2.2. AGENTS WITH PERIPHERAL ACTION	55
2.2.1. <i>Bradikinin receptor antagonists</i>	55
2.2.2. <i>Antagonists of prostaglandins and other eicosanoids</i>	56
2.2.3. <i>Inhibitors of post-translational processing of cytokines</i>	66
2.2.4. <i>Ion channel modulators</i>	69
2.2.5. <i>Opioid action at the peripheral level</i>	71
2.2.6. <i>Capsaicine</i>	72
2.3. CENTRAL-ACTING AGENTS	73
2.3.1. <i>Neuropeptides and neuropeptide antagonists</i>	73

2.3.2. <i>Other neuropeptids</i>	76
2.3.3. <i>Antagonists of excitatory aminoacids</i>	79
2.3.4. <i>Adenosine analogues</i>	79
2.3.5. <i>Adrenergic receptors agonists</i>	80
2.3.6. <i>Other possibilities</i>	81
3. IMMUNE ACTIVATION - ROLE OF IMMUNOLOGIC MEDIATORS IN INFLAMMATION AND PAIN	83
VERONICA BILD	
3.1. INTRODUCTION	83
3.2. IMMUNE RESPONSE	83
3.2.1. <i>First level of immune defense</i>	84
3.2.2. <i>Second level of immune defense</i>	84
3.2.3. <i>Third level of immune defense</i>	86
3.3. IMPLICATIONS OF IMMUNE/INFLAMMATORY REACTIONS IN INFLAMMATORY HYPERALGESIA	86
3.3.1. <i>Contribution of „immune-like” glial cells from the CNS in chronic pain</i>	89
3.3.2. <i>Influence of spinal glial activation on pain perception</i>	90
3.4. POTENTIAL PHARMACOLOGICAL POSSIBILITIES IN THE CONTROL OF PATHOLOGIC PAIN, TARGETING THE PROCESS OF GLIAL ACTIVATION	92
3.4.1. <i>Agents disturbing glial activation</i>	94
3.4.2. <i>Antagonists of pro-inflammatory cytokines</i>	95
3.4.3. <i>Pro-inflammatory cytokines synthesis inhibitors</i>	96
3.4.4. <i>Disturbance of synthesis and stimulus transfer involved in the activity of pro-inflammatory cytokines</i>	96
4. NON-OPIATE ANALGESICS	111
MIRCEA D.G PAVELESCU	
4.1. HISTORY	111
4.2. ANALGESICS-ANTIPYRETICS	113
4.2.1. <i>Definition</i>	113
4.2.2. <i>Classification</i>	114
4.2.3. <i>Pharmacodynamics</i>	114
4.2.4. <i>Pharmacotoxicology</i>	116
4.2.5. <i>Pharmacoterapy</i>	117
4.2.6. <i>Salicylic acid derivatives</i>	118
4.2.7. <i>Pyrazolone derivatives</i>	122
4.2.8. <i>p-aminophenol derivatives</i>	124
4.3. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID)	126
4.3.1. <i>Definition</i>	126
4.3.2. <i>Pathophysiological bases</i>	127
4.3.3. <i>Classification</i>	128
4.3.4. <i>Pharmacokinetics</i>	128
4.3.5. <i>Pharmacodynamics</i>	129
4.3.6. <i>Pharmacotoxicology</i>	131

4.3.7. Pharmacotherapy	131
4.3.8. Pharmacoepidemiology	132
4.3.9. Classic non-steroidal anti-inflammatories (NSAID)	133
5. OPIOID ANALGESICS	148
OSTIN C. MUNGIU	
5.1 INTRODUCTION. HISTORY	148
5.2. DEFINITION	149
5.3. CLASSIFICATION	149
5.4. PHARMACOKINETICS	149
5.4.1. Absorption. Administration pathways	150
5.4.2. Transport and distribution	153
5.4.3. Metabolism	154
5.4.4. Elimination	155
5.5. ACTION MECHANISM OPIOID RECEPTORS	156
5.6. PHARMACODYNAMICS	159
5.6.1. CNS effects	159
5.6.2. Peripheral effects	159
5.6.3. Tolerance, addiction	160
5.6.4. Opiate addiction treatment	161
5.7. INDICATIONS, CONTRAINDICATIONS, ADVERSE REACTIONS, DRUG INTERACTIONS	163
5.7.1. Opioid analgesics indications and contraindications	163
5.7.2. Adverse reactions. Combatting adverse reactions	163
5.7.3. Drug interactions	169
5.8 LEGISLATIVE ASPECTS	170
6. ORTHOMOLECULAR THERAPY IN INFLAMMATORY DISEASE	186
MONICA HĂNCEANU	
7. PAIN TREATMENT IN CANCER	199
EDUARD BILD	
8. GYNECOLOGIC PAIN	222
CĂTĂLIN RADU MIHĂILĂ	
9. PAIN IN CHILDREN	238
BOGDAN SAVU	
10. ROLE OF PHARMACIST-PACIENT COMMUNICAT IN PAIN MANAGEMENT	248
ILEANA COJOCARU	